Effects of a New Emollient-Based Treatment on Skin Microflora Balance and Barrier Function in Children with Mild Atopic Dermatitis

Background/Objectives The use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin microflora is suspected of playing a key role in exacerbations of AD. Our aim was to evaluate the effect of a new emollient balm on clinical...

Full description

Saved in:
Bibliographic Details
Published inPediatric dermatology Vol. 33; no. 2; pp. 165 - 171
Main Authors Bianchi, Pascale, Theunis, Jennifer, Casas, Christiane, Villeneuve, Cecile, Patrizi, Annalisa, Phulpin, Chloe, Bacquey, Adeline, Redoulès, Daniel, Mengeaud, Valerie, Schmitt, Anne-Marie
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.03.2016
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background/Objectives The use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin microflora is suspected of playing a key role in exacerbations of AD. Our aim was to evaluate the effect of a new emollient balm on clinical parameters (SCORing Atopic Dermatitis [SCORAD], xerosis, pruritus), skin barrier function (transepidermal water loss and loricrin, filaggrin, corneodesmosin, and involucrin expression], skin microflora biodiversity, and Staphylococcus aureus and Staphylococcus epidermidis balance in children with mild AD. Methods Fifty‐four children (1–4 yrs old) were enrolled in this randomized, controlled study. Subjects applied a hygiene product and the emollient balm (emollient group, n = 28) or the hygiene product only (control group, n = 26) twice a day for 28 days. Results We found improvement in favor of the emollient group in SCORAD (p < 0.001), pruritus (p = 0.06), and xerosis (p = 0.06) after 28 days of application. Moreover, transepidermal water loss decreased in the emollient group by 34% (p = 0.06) and involucrin expression by 37% (p = 0.001) at day 28 from baseline in association with improvement in barrier function, whereas other barrier‐specific proteins did not vary. S. aureus increased significantly in the control group only (6.5 times, p = 0.01), whereas S. epidermidis remained stable in both groups. The Shannon index (H′ = 2.3) did not vary with treatment in either group. Conclusion Twice‐daily application of a new emollient balm in children with mild AD protected the skin from S. aureus proliferation and preserved microflora biodiversity.
AbstractList The use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin microflora is suspected of playing a key role in exacerbations of AD. Our aim was to evaluate the effect of a new emollient balm on clinical parameters (SCORing Atopic Dermatitis [SCORAD], xerosis, pruritus), skin barrier function (transepidermal water loss and loricrin, filaggrin, corneodesmosin, and involucrin expression], skin microflora biodiversity, and Staphylococcus aureus and Staphylococcus epidermidis balance in children with mild AD. Fifty-four children (1-4 yrs old) were enrolled in this randomized, controlled study. Subjects applied a hygiene product and the emollient balm (emollient group, n = 28) or the hygiene product only (control group, n = 26) twice a day for 28 days. We found improvement in favor of the emollient group in SCORAD (p < 0.001), pruritus (p = 0.06), and xerosis (p = 0.06) after 28 days of application. Moreover, transepidermal water loss decreased in the emollient group by 34% (p = 0.06) and involucrin expression by 37% (p = 0.001) at day 28 from baseline in association with improvement in barrier function, whereas other barrier-specific proteins did not vary. S. aureus increased significantly in the control group only (6.5 times, p = 0.01), whereas S. epidermidis remained stable in both groups. The Shannon index (H' = 2.3) did not vary with treatment in either group. Twice-daily application of a new emollient balm in children with mild AD protected the skin from S. aureus proliferation and preserved microflora biodiversity.
Background/Objectives The use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin microflora is suspected of playing a key role in exacerbations of AD. Our aim was to evaluate the effect of a new emollient balm on clinical parameters (SCORing Atopic Dermatitis [SCORAD], xerosis, pruritus), skin barrier function (transepidermal water loss and loricrin, filaggrin, corneodesmosin, and involucrin expression], skin microflora biodiversity, and Staphylococcus aureus and Staphylococcus epidermidis balance in children with mild AD. Methods Fifty‐four children (1–4 yrs old) were enrolled in this randomized, controlled study. Subjects applied a hygiene product and the emollient balm (emollient group, n = 28) or the hygiene product only (control group, n = 26) twice a day for 28 days. Results We found improvement in favor of the emollient group in SCORAD (p < 0.001), pruritus (p = 0.06), and xerosis (p = 0.06) after 28 days of application. Moreover, transepidermal water loss decreased in the emollient group by 34% (p = 0.06) and involucrin expression by 37% (p = 0.001) at day 28 from baseline in association with improvement in barrier function, whereas other barrier‐specific proteins did not vary. S. aureus increased significantly in the control group only (6.5 times, p = 0.01), whereas S. epidermidis remained stable in both groups. The Shannon index (H′ = 2.3) did not vary with treatment in either group. Conclusion Twice‐daily application of a new emollient balm in children with mild AD protected the skin from S. aureus proliferation and preserved microflora biodiversity.
The use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin microflora is suspected of playing a key role in exacerbations of AD. Our aim was to evaluate the effect of a new emollient balm on clinical parameters (SCORing Atopic Dermatitis [SCORAD], xerosis, pruritus), skin barrier function (transepidermal water loss and loricrin, filaggrin, corneodesmosin, and involucrin expression], skin microflora biodiversity, and Staphylococcus aureus and Staphylococcus epidermidis balance in children with mild AD.BACKGROUND/OBJECTIVESThe use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin microflora is suspected of playing a key role in exacerbations of AD. Our aim was to evaluate the effect of a new emollient balm on clinical parameters (SCORing Atopic Dermatitis [SCORAD], xerosis, pruritus), skin barrier function (transepidermal water loss and loricrin, filaggrin, corneodesmosin, and involucrin expression], skin microflora biodiversity, and Staphylococcus aureus and Staphylococcus epidermidis balance in children with mild AD.Fifty-four children (1-4 yrs old) were enrolled in this randomized, controlled study. Subjects applied a hygiene product and the emollient balm (emollient group, n = 28) or the hygiene product only (control group, n = 26) twice a day for 28 days.METHODSFifty-four children (1-4 yrs old) were enrolled in this randomized, controlled study. Subjects applied a hygiene product and the emollient balm (emollient group, n = 28) or the hygiene product only (control group, n = 26) twice a day for 28 days.We found improvement in favor of the emollient group in SCORAD (p < 0.001), pruritus (p = 0.06), and xerosis (p = 0.06) after 28 days of application. Moreover, transepidermal water loss decreased in the emollient group by 34% (p = 0.06) and involucrin expression by 37% (p = 0.001) at day 28 from baseline in association with improvement in barrier function, whereas other barrier-specific proteins did not vary. S. aureus increased significantly in the control group only (6.5 times, p = 0.01), whereas S. epidermidis remained stable in both groups. The Shannon index (H' = 2.3) did not vary with treatment in either group.RESULTSWe found improvement in favor of the emollient group in SCORAD (p < 0.001), pruritus (p = 0.06), and xerosis (p = 0.06) after 28 days of application. Moreover, transepidermal water loss decreased in the emollient group by 34% (p = 0.06) and involucrin expression by 37% (p = 0.001) at day 28 from baseline in association with improvement in barrier function, whereas other barrier-specific proteins did not vary. S. aureus increased significantly in the control group only (6.5 times, p = 0.01), whereas S. epidermidis remained stable in both groups. The Shannon index (H' = 2.3) did not vary with treatment in either group.Twice-daily application of a new emollient balm in children with mild AD protected the skin from S. aureus proliferation and preserved microflora biodiversity.CONCLUSIONTwice-daily application of a new emollient balm in children with mild AD protected the skin from S. aureus proliferation and preserved microflora biodiversity.
Author Schmitt, Anne-Marie
Redoulès, Daniel
Villeneuve, Cecile
Bacquey, Adeline
Bianchi, Pascale
Phulpin, Chloe
Theunis, Jennifer
Patrizi, Annalisa
Casas, Christiane
Mengeaud, Valerie
AuthorAffiliation 2 Department of Dermatology University of Bologna Bologna Italy
1 European Center for Skin Research Pierre Fabre Dermo‐Cosmétique Toulouse France
AuthorAffiliation_xml – name: 1 European Center for Skin Research Pierre Fabre Dermo‐Cosmétique Toulouse France
– name: 2 Department of Dermatology University of Bologna Bologna Italy
Author_xml – sequence: 1
  givenname: Pascale
  surname: Bianchi
  fullname: Bianchi, Pascale
  organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France
– sequence: 2
  givenname: Jennifer
  surname: Theunis
  fullname: Theunis, Jennifer
  email: jennifer.theunis@pierre-fabre.com
  organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France
– sequence: 3
  givenname: Christiane
  surname: Casas
  fullname: Casas, Christiane
  organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France
– sequence: 4
  givenname: Cecile
  surname: Villeneuve
  fullname: Villeneuve, Cecile
  organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France
– sequence: 5
  givenname: Annalisa
  surname: Patrizi
  fullname: Patrizi, Annalisa
  organization: Department of Dermatology, University of Bologna, Bologna, Italy
– sequence: 6
  givenname: Chloe
  surname: Phulpin
  fullname: Phulpin, Chloe
  organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France
– sequence: 7
  givenname: Adeline
  surname: Bacquey
  fullname: Bacquey, Adeline
  organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France
– sequence: 8
  givenname: Daniel
  surname: Redoulès
  fullname: Redoulès, Daniel
  organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France
– sequence: 9
  givenname: Valerie
  surname: Mengeaud
  fullname: Mengeaud, Valerie
  organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France
– sequence: 10
  givenname: Anne-Marie
  surname: Schmitt
  fullname: Schmitt, Anne-Marie
  organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27001317$$D View this record in MEDLINE/PubMed
BookMark eNp1kU9vEzEQxS1URNPCgS-AfITDtvb-sTcXpDZNU1BbkAhwtLz2LDH12sF2CL32k-OSpAIEvtjW_N4bzZsDtOe8A4SeU3JE8zleajiiJW_ZIzSiTdkUtOZkD40Ir1jRkprto4MYvxJCWsboE7RfckJoRfkI3U37HlSK2PdY4mtY4-ngrTXgUnEqI2g8DyDTkP_YO_zhxjh8ZVTwvfVB4lNppVOApdP5HYKBgM9XTiWT4YxOFsbqAA6vTVpkodX4JPmlUfgMwiCTSSY-RY97aSM8296H6OP5dD65KC7fzd5MTi4LVTd5jo41taZ1LTVrupr1FRu3mpRcMVJxMs6DkZJWHaOtUiUQrrq21wp4Oe6prru-OkSvN77LVTdALrkUpBXLYAYZboWXRvxZcWYhvvjvoiGc8pJlg5dbg-C_rSAmMZiowOYIwK-ioJw3VUsprzP64vdeD012wWfgeAPkKGMM0AtlkryPLbc2VlAi7lcr8mrFr9Vmxau_FDvTf7Fb97WxcPt_ULw_m-4UxUZhYoIfDwoZbgTjFW_E5-uZmNC3M_ppciXm1U8MSsLA
CitedBy_id crossref_primary_10_1080_09546634_2017_1328938
crossref_primary_10_1016_j_aller_2018_06_008
crossref_primary_10_1097_DER_0000000000000589
crossref_primary_10_1007_s13555_022_00685_2
crossref_primary_10_25259_IJDVL_1384_20
crossref_primary_10_1111_jdv_18947
crossref_primary_10_1080_09546634_2018_1516030
crossref_primary_10_15690_vsp_v19i4S_2144
crossref_primary_10_1111_jdv_18949
crossref_primary_10_15690_vsp_v21i5_2449
crossref_primary_10_1016_S0151_9638_17_31042_6
crossref_primary_10_1111_exd_13336
crossref_primary_10_15690_pf_v16i2_2006
crossref_primary_10_3389_fphys_2024_1322205
crossref_primary_10_1055_a_2104_2848
crossref_primary_10_1080_09546634_2019_1708246
crossref_primary_10_1002_14651858_CD012119_pub2
crossref_primary_10_3390_jcm11174974
crossref_primary_10_1016_j_micpath_2024_107163
crossref_primary_10_15690_pf_v16i5_2060
crossref_primary_10_1007_s40257_020_00551_x
crossref_primary_10_15690_vsp_v19i6_2144
crossref_primary_10_1111_jdv_14891
crossref_primary_10_1111_jdv_19125
crossref_primary_10_1080_13543784_2018_1494723
crossref_primary_10_3390_cosmetics9040075
crossref_primary_10_1111_bjd_15390
crossref_primary_10_1155_2023_2375223
crossref_primary_10_1111_exd_14435
crossref_primary_10_1007_s13671_024_00453_9
crossref_primary_10_1515_sjdv_2016_0012
crossref_primary_10_15690_vsp_v20i5_2309
crossref_primary_10_1007_s40257_020_00529_9
crossref_primary_10_1080_17843286_2023_2285576
crossref_primary_10_1007_s13555_020_00415_6
crossref_primary_10_3390_jcm13082185
crossref_primary_10_1007_s13555_024_01119_x
crossref_primary_10_1016_j_anai_2017_09_061
crossref_primary_10_34883_PI_2020_23_1_013
crossref_primary_10_3390_jcm13030863
crossref_primary_10_1007_s13555_018_0243_4
crossref_primary_10_1111_jdv_16083
Cites_doi 10.1016/j.jaci.2007.12.1161
10.1016/j.jaci.2014.08.008
10.4168/aair.2014.6.4.276
10.1111/j.1365-2133.2007.08112.x
10.1159/000245677
10.1111/j.1468-3083.2012.04635.x
10.1016/j.jaci.2012.12.672
10.1186/1471-2180-10-206
10.1016/j.jaci.2007.08.067
10.1159/000247298
10.5021/ad.2012.24.4.413
10.1128/IAI.01304-08
10.1046/j.1365-2222.2000.00848.x
10.1101/gr.131029.111
10.1159/000143391
10.1111/j.1468-3083.2009.03415.x
10.1111/j.1600-0625.2011.01417.x
10.1016/j.clindermatol.2011.08.015
10.1016/j.jaci.2013.07.008
10.1038/jid.2011.306
10.2165/00128071-200809010-00005
10.1038/jid.2009.133
ContentType Journal Article
Copyright 2016 Pierre Fabre Dermo‐Cosmétique. published by Wiley Periodicals, Inc.
2016 Pierre Fabre Dermo-Cosmétique. Pediatric Dermatology published by Wiley Periodicals, Inc.
Copyright_xml – notice: 2016 Pierre Fabre Dermo‐Cosmétique. published by Wiley Periodicals, Inc.
– notice: 2016 Pierre Fabre Dermo-Cosmétique. Pediatric Dermatology published by Wiley Periodicals, Inc.
DBID BSCLL
24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1111/pde.12786
DatabaseName Istex
Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Bianchi et al
EISSN 1525-1470
EndPage 171
ExternalDocumentID PMC5071726
27001317
10_1111_pde_12786
PDE12786
ark_67375_WNG_C1JG1VCM_T
Genre article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Pierre Fabre Dermo‐Cosmétique
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
123
1OB
1OC
29O
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAKAS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABPPZ
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZCM
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHEFC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
CYRXZ
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
L7B
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
UB1
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YFH
ZGI
ZXP
ZZTAW
~IA
~WT
24P
AAHQN
AAIPD
AAMNL
AANHP
AAYCA
ACRPL
ACYXJ
ADNMO
AFWVQ
ALVPJ
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
5PM
ID FETCH-LOGICAL-c4536-b654d144ad65b46f3698d027c6037096610213b618cc2e07cb8fdce729f1d4bf3
IEDL.DBID DR2
ISSN 0736-8046
1525-1470
IngestDate Thu Aug 21 14:20:22 EDT 2025
Fri Jul 11 07:55:26 EDT 2025
Wed Feb 19 01:55:55 EST 2025
Tue Jul 01 01:46:15 EDT 2025
Thu Apr 24 23:01:20 EDT 2025
Wed Jan 22 16:32:40 EST 2025
Wed Oct 30 09:50:58 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License Attribution-NonCommercial
http://creativecommons.org/licenses/by-nc/4.0
2016 Pierre Fabre Dermo-Cosmétique. Pediatric Dermatology published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4536-b654d144ad65b46f3698d027c6037096610213b618cc2e07cb8fdce729f1d4bf3
Notes Pierre Fabre Dermo-Cosmétique
ArticleID:PDE12786
istex:1AE044DD90E23D377EC85C492421648E00A02626
ark:/67375/WNG-C1JG1VCM-T
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
These authors contributed equally to this work.
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fpde.12786
PMID 27001317
PQID 1775381174
PQPubID 23479
PageCount 7
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5071726
proquest_miscellaneous_1775381174
pubmed_primary_27001317
crossref_citationtrail_10_1111_pde_12786
crossref_primary_10_1111_pde_12786
wiley_primary_10_1111_pde_12786_PDE12786
istex_primary_ark_67375_WNG_C1JG1VCM_T
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March/April 2016
PublicationDateYYYYMMDD 2016-03-01
PublicationDate_xml – month: 03
  year: 2016
  text: March/April 2016
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Pediatric dermatology
PublicationTitleAlternate Pediatr Dermatol
PublicationYear 2016
Publisher Blackwell Publishing Ltd
John Wiley and Sons Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: John Wiley and Sons Inc
References Cork MJ, Danby SG, Vasilopoulos Y et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009;129:1892-1908.
Kong HH, Oh J, Deming C et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012;22:850-859.
Kunz B, Oranje AP, Labreze L et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10-19.
Grzanka A, Zebracka-Gala J, Rachowska R et al. The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions. Exp Dermatol 2012;21:184-188.
Gupta J, Grube E, Ericksen MB et al. Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity. J Allergy Clin Immunol 2008;121:725-730. e722
Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol 2014;134:769-779.
Wu GD, Lewis JD, Hoffmann C et al. Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16s sequence tags. BMC Microbiol 2010;10:206.
Oranje AP, Glazenburg EJ, Wolkerstorfer A et al. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007;157:645-648.
Schneider L, Tilles S, Lio P et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013;131:295-299. e1-e27
Darsow U, Wollenberg A, Simon D et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010;24:317-328.
Lee HJ, Lee SH. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol Res 2014;6:276-287.
Hon KL, Wong KY, Leung TF et al. Comparison of skin hydration evaluation sites and correlations among skin hydration, transepidermal water loss, SCORAD index, Nottingham Eczema Severity Score, and quality of life in patients with atopic dermatitis. Am J Clin Dermatol 2008;9:45-50.
Loden M. Effect of moisturizers on epidermal barrier function. Clin Dermatol 2012;30:286-296.
Schmitt J, Langan S, Deckert S et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 2013;132:1337-1347.
Baurecht H, Irvine AD, Novak N et al. Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol 2007;120:1406-1412.
Clarke SR, Andre G, Walsh EJ et al. Iron-regulated surface determinant protein a mediates adhesion of Staphylococcus aureus to human corneocyte envelope proteins. Infect Immun 2009;77:2408-2416.
Stalder JF, Taïeb A. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23-31.
Na SY, Roh JY, Kim JM et al. Analysis of colonization and genotyping of the exotoxins of Staphylococcus aureus in patients with atopic dermatitis. Ann Dermatol 2012;24:413-419.
Bianchi P, Ribet V, Casas C et al. Analysis of gene expression in atopic dermatitis using a microabrasive method. J Invest Dermatol 2012;132:469-472.
Zollner TM, Wichelhaus TA, Hartung A et al. Colonization with superantigen-producing Staphylococcus aureus is associated with increased severity of atopic dermatitis. Clin Exp Allergy 2000;30:994-1000.
Casas C, Ginisty H, Alvarez-Georges S et al. Molecular characterization of inflammation and Staphylococcus aureus colonization of involved skin of atopic dermatitis patients. A non-invasive approach. Skin Pharmacol Physiol 2008;21:260-268.
Ring J, Alomar A, Bieber T et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012;26:1045-1060.
2009; 77
2010; 10
2007; 157
2012; 132
2010; 24
1997; 195
2000; 30
2007; 120
2008; 9
2008; 21
2013; 132
2012; 26
2013; 131
2009; 129
2012; 24
2008; 121
2012; 22
2014; 6
2012; 21
1993; 186
2014; 134
2012; 30
e_1_2_6_21_1
e_1_2_6_10_1
e_1_2_6_20_1
e_1_2_6_9_1
e_1_2_6_8_1
e_1_2_6_19_1
e_1_2_6_5_1
e_1_2_6_4_1
e_1_2_6_7_1
e_1_2_6_6_1
e_1_2_6_13_1
e_1_2_6_14_1
e_1_2_6_3_1
e_1_2_6_11_1
e_1_2_6_23_1
e_1_2_6_2_1
e_1_2_6_12_1
e_1_2_6_22_1
e_1_2_6_17_1
e_1_2_6_18_1
e_1_2_6_15_1
e_1_2_6_16_1
24035157 - J Allergy Clin Immunol. 2013 Dec;132(6):1337-47
9267730 - Dermatology. 1997;195(1):10-9
17714568 - Br J Dermatol. 2007 Oct;157(4):645-8
21956121 - J Invest Dermatol. 2012 Feb;132(2):469-72
10848922 - Clin Exp Allergy. 2000 Jul;30(7):994-1000
20673359 - BMC Microbiol. 2010 Jul 30;10:206
19494826 - J Invest Dermatol. 2009 Aug;129(8):1892-908
22310478 - Genome Res. 2012 May;22(5):850-9
18249438 - J Allergy Clin Immunol. 2008 Mar;121(3):725-730.e2
19732254 - J Eur Acad Dermatol Venereol. 2010 Mar;24(3):317-28
17980411 - J Allergy Clin Immunol. 2007 Dec;120(6):1406-12
18092843 - Am J Clin Dermatol. 2008;9(1):45-50
23197906 - Ann Dermatol. 2012 Nov;24(4):413-9
18612217 - Skin Pharmacol Physiol. 2008;21(5):260-8
22142393 - Exp Dermatol. 2012 Mar;21(3):184-8
25282559 - J Allergy Clin Immunol. 2014 Oct;134(4):769-79
19307218 - Infect Immun. 2009 Jun;77(6):2408-16
22805051 - J Eur Acad Dermatol Venereol. 2012 Aug;26(8):1045-60
24991450 - Allergy Asthma Immunol Res. 2014 Jul;6(4):276-87
23374261 - J Allergy Clin Immunol. 2013 Feb;131(2):295-9.e1-27
8435513 - Dermatology. 1993;186(1):23-31
22507043 - Clin Dermatol. 2012 May-Jun;30(3):286-96
References_xml – reference: Casas C, Ginisty H, Alvarez-Georges S et al. Molecular characterization of inflammation and Staphylococcus aureus colonization of involved skin of atopic dermatitis patients. A non-invasive approach. Skin Pharmacol Physiol 2008;21:260-268.
– reference: Loden M. Effect of moisturizers on epidermal barrier function. Clin Dermatol 2012;30:286-296.
– reference: Zollner TM, Wichelhaus TA, Hartung A et al. Colonization with superantigen-producing Staphylococcus aureus is associated with increased severity of atopic dermatitis. Clin Exp Allergy 2000;30:994-1000.
– reference: Cork MJ, Danby SG, Vasilopoulos Y et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009;129:1892-1908.
– reference: Bianchi P, Ribet V, Casas C et al. Analysis of gene expression in atopic dermatitis using a microabrasive method. J Invest Dermatol 2012;132:469-472.
– reference: Wu GD, Lewis JD, Hoffmann C et al. Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16s sequence tags. BMC Microbiol 2010;10:206.
– reference: Schmitt J, Langan S, Deckert S et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 2013;132:1337-1347.
– reference: Baurecht H, Irvine AD, Novak N et al. Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol 2007;120:1406-1412.
– reference: Ring J, Alomar A, Bieber T et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012;26:1045-1060.
– reference: Na SY, Roh JY, Kim JM et al. Analysis of colonization and genotyping of the exotoxins of Staphylococcus aureus in patients with atopic dermatitis. Ann Dermatol 2012;24:413-419.
– reference: Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol 2014;134:769-779.
– reference: Grzanka A, Zebracka-Gala J, Rachowska R et al. The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions. Exp Dermatol 2012;21:184-188.
– reference: Stalder JF, Taïeb A. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23-31.
– reference: Clarke SR, Andre G, Walsh EJ et al. Iron-regulated surface determinant protein a mediates adhesion of Staphylococcus aureus to human corneocyte envelope proteins. Infect Immun 2009;77:2408-2416.
– reference: Lee HJ, Lee SH. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol Res 2014;6:276-287.
– reference: Hon KL, Wong KY, Leung TF et al. Comparison of skin hydration evaluation sites and correlations among skin hydration, transepidermal water loss, SCORAD index, Nottingham Eczema Severity Score, and quality of life in patients with atopic dermatitis. Am J Clin Dermatol 2008;9:45-50.
– reference: Darsow U, Wollenberg A, Simon D et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010;24:317-328.
– reference: Gupta J, Grube E, Ericksen MB et al. Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity. J Allergy Clin Immunol 2008;121:725-730. e722
– reference: Kong HH, Oh J, Deming C et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012;22:850-859.
– reference: Schneider L, Tilles S, Lio P et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013;131:295-299. e1-e27
– reference: Kunz B, Oranje AP, Labreze L et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10-19.
– reference: Oranje AP, Glazenburg EJ, Wolkerstorfer A et al. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007;157:645-648.
– volume: 131
  start-page: 295
  year: 2013
  end-page: 299
  article-title: Atopic dermatitis: a practice parameter update 2012
  publication-title: J Allergy Clin Immunol
– volume: 30
  start-page: 286
  year: 2012
  end-page: 296
  article-title: Effect of moisturizers on epidermal barrier function
  publication-title: Clin Dermatol
– volume: 132
  start-page: 469
  year: 2012
  end-page: 472
  article-title: Analysis of gene expression in atopic dermatitis using a microabrasive method
  publication-title: J Invest Dermatol
– volume: 121
  start-page: 725
  year: 2008
  end-page: 730
  article-title: Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity
  publication-title: J Allergy Clin Immunol
– volume: 24
  start-page: 413
  year: 2012
  end-page: 419
  article-title: Analysis of colonization and genotyping of the exotoxins of in patients with atopic dermatitis
  publication-title: Ann Dermatol
– volume: 26
  start-page: 1045
  year: 2012
  end-page: 1060
  article-title: Guidelines for treatment of atopic eczema (atopic dermatitis) part I
  publication-title: J Eur Acad Dermatol Venereol
– volume: 10
  start-page: 206
  year: 2010
  article-title: Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16s sequence tags
  publication-title: BMC Microbiol
– volume: 186
  start-page: 23
  year: 1993
  end-page: 31
  article-title: Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis
  publication-title: Dermatology
– volume: 129
  start-page: 1892
  year: 2009
  end-page: 1908
  article-title: Epidermal barrier dysfunction in atopic dermatitis
  publication-title: J Invest Dermatol
– volume: 120
  start-page: 1406
  year: 2007
  end-page: 1412
  article-title: Toward a major risk factor for atopic eczema: meta‐analysis of filaggrin polymorphism data
  publication-title: J Allergy Clin Immunol
– volume: 9
  start-page: 45
  year: 2008
  end-page: 50
  article-title: Comparison of skin hydration evaluation sites and correlations among skin hydration, transepidermal water loss, SCORAD index, Nottingham Eczema Severity Score, and quality of life in patients with atopic dermatitis
  publication-title: Am J Clin Dermatol
– volume: 30
  start-page: 994
  year: 2000
  end-page: 1000
  article-title: Colonization with superantigen‐producing is associated with increased severity of atopic dermatitis
  publication-title: Clin Exp Allergy
– volume: 134
  start-page: 769
  year: 2014
  end-page: 779
  article-title: Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches
  publication-title: J Allergy Clin Immunol
– volume: 24
  start-page: 317
  year: 2010
  end-page: 328
  article-title: ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis
  publication-title: J Eur Acad Dermatol Venereol
– volume: 157
  start-page: 645
  year: 2007
  end-page: 648
  article-title: Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three‐item severity score
  publication-title: Br J Dermatol
– volume: 21
  start-page: 260
  year: 2008
  end-page: 268
  article-title: Molecular characterization of inflammation and colonization of involved skin of atopic dermatitis patients. A non‐invasive approach
  publication-title: Skin Pharmacol Physiol
– volume: 6
  start-page: 276
  year: 2014
  end-page: 287
  article-title: Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis
  publication-title: Allergy Asthma Immunol Res
– volume: 132
  start-page: 1337
  year: 2013
  end-page: 1347
  article-title: Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation
  publication-title: J Allergy Clin Immunol
– volume: 21
  start-page: 184
  year: 2012
  end-page: 188
  article-title: The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions
  publication-title: Exp Dermatol
– volume: 77
  start-page: 2408
  year: 2009
  end-page: 2416
  article-title: Iron‐regulated surface determinant protein a mediates adhesion of to human corneocyte envelope proteins
  publication-title: Infect Immun
– volume: 195
  start-page: 10
  year: 1997
  end-page: 19
  article-title: Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis
  publication-title: Dermatology
– volume: 22
  start-page: 850
  year: 2012
  end-page: 859
  article-title: Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis
  publication-title: Genome Res
– ident: e_1_2_6_19_1
  doi: 10.1016/j.jaci.2007.12.1161
– ident: e_1_2_6_3_1
  doi: 10.1016/j.jaci.2014.08.008
– ident: e_1_2_6_10_1
  doi: 10.4168/aair.2014.6.4.276
– ident: e_1_2_6_16_1
  doi: 10.1111/j.1365-2133.2007.08112.x
– ident: e_1_2_6_12_1
  doi: 10.1159/000245677
– ident: e_1_2_6_7_1
  doi: 10.1111/j.1468-3083.2012.04635.x
– ident: e_1_2_6_8_1
  doi: 10.1016/j.jaci.2012.12.672
– ident: e_1_2_6_15_1
  doi: 10.1186/1471-2180-10-206
– ident: e_1_2_6_21_1
  doi: 10.1016/j.jaci.2007.08.067
– ident: e_1_2_6_11_1
  doi: 10.1159/000247298
– ident: e_1_2_6_17_1
  doi: 10.5021/ad.2012.24.4.413
– ident: e_1_2_6_22_1
  doi: 10.1128/IAI.01304-08
– ident: e_1_2_6_5_1
  doi: 10.1046/j.1365-2222.2000.00848.x
– ident: e_1_2_6_4_1
  doi: 10.1101/gr.131029.111
– ident: e_1_2_6_6_1
  doi: 10.1159/000143391
– ident: e_1_2_6_9_1
  doi: 10.1111/j.1468-3083.2009.03415.x
– ident: e_1_2_6_20_1
  doi: 10.1111/j.1600-0625.2011.01417.x
– ident: e_1_2_6_23_1
  doi: 10.1016/j.clindermatol.2011.08.015
– ident: e_1_2_6_13_1
  doi: 10.1016/j.jaci.2013.07.008
– ident: e_1_2_6_14_1
  doi: 10.1038/jid.2011.306
– ident: e_1_2_6_18_1
  doi: 10.2165/00128071-200809010-00005
– ident: e_1_2_6_2_1
  doi: 10.1038/jid.2009.133
– reference: 18612217 - Skin Pharmacol Physiol. 2008;21(5):260-8
– reference: 19732254 - J Eur Acad Dermatol Venereol. 2010 Mar;24(3):317-28
– reference: 25282559 - J Allergy Clin Immunol. 2014 Oct;134(4):769-79
– reference: 17714568 - Br J Dermatol. 2007 Oct;157(4):645-8
– reference: 17980411 - J Allergy Clin Immunol. 2007 Dec;120(6):1406-12
– reference: 21956121 - J Invest Dermatol. 2012 Feb;132(2):469-72
– reference: 8435513 - Dermatology. 1993;186(1):23-31
– reference: 19494826 - J Invest Dermatol. 2009 Aug;129(8):1892-908
– reference: 22142393 - Exp Dermatol. 2012 Mar;21(3):184-8
– reference: 22507043 - Clin Dermatol. 2012 May-Jun;30(3):286-96
– reference: 9267730 - Dermatology. 1997;195(1):10-9
– reference: 18092843 - Am J Clin Dermatol. 2008;9(1):45-50
– reference: 23374261 - J Allergy Clin Immunol. 2013 Feb;131(2):295-9.e1-27
– reference: 18249438 - J Allergy Clin Immunol. 2008 Mar;121(3):725-730.e2
– reference: 19307218 - Infect Immun. 2009 Jun;77(6):2408-16
– reference: 22310478 - Genome Res. 2012 May;22(5):850-9
– reference: 22805051 - J Eur Acad Dermatol Venereol. 2012 Aug;26(8):1045-60
– reference: 10848922 - Clin Exp Allergy. 2000 Jul;30(7):994-1000
– reference: 24991450 - Allergy Asthma Immunol Res. 2014 Jul;6(4):276-87
– reference: 24035157 - J Allergy Clin Immunol. 2013 Dec;132(6):1337-47
– reference: 20673359 - BMC Microbiol. 2010 Jul 30;10:206
– reference: 23197906 - Ann Dermatol. 2012 Nov;24(4):413-9
SSID ssj0008661
Score 2.314728
Snippet Background/Objectives The use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin...
The use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin microflora is...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
istex
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 165
SubjectTerms Child, Preschool
Dermatitis, Atopic - drug therapy
Emollients - administration & dosage
Humans
Infant
Original
Skin - drug effects
Skin - microbiology
Staphylococcus aureus - drug effects
Staphylococcus epidermidis - drug effects
Title Effects of a New Emollient-Based Treatment on Skin Microflora Balance and Barrier Function in Children with Mild Atopic Dermatitis
URI https://api.istex.fr/ark:/67375/WNG-C1JG1VCM-T/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fpde.12786
https://www.ncbi.nlm.nih.gov/pubmed/27001317
https://www.proquest.com/docview/1775381174
https://pubmed.ncbi.nlm.nih.gov/PMC5071726
Volume 33
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEB9qBfHF-llTtawi4kuOS7LZTelTe71rKVwpctU-CCH7ETx6Jsd9gPjkQ_-A_o39S5zZfNjTCuJbILNJdjOz85vd2d8AvCW3g46fGC6l8rmUmZ8YHfk6UgkPQyVjS-sdwxNxdMaPz-PzNdhtzsJU_BDtghtZhpuvycAzNb9h5FNjO0GIb8L5l3K1CBB9-EUdlQjHlYoaTIS7XNSsQpTF07Zc8UV3aVi_3QY0_8yXvIljnSMabMDnpgtV_slFZ7lQHf39N3bH_-zjQ3hQA1S2V2nUI1izxWO4N6y34J_AZcV3PGdlzjKGcyTrfyVib_zo6x9X--gUDRs12eusLBiV92JDyvvLJ6hvbJ-SKbVlWWHwekYV89gAvStpCEPRXn28nNESMTacGLa3KKdjzQ5sha_H86dwNuiPekd-XcrB1zzGP6BEzA3GbpkRseIij8ROYjAi1qIbSYyiBFUYj5QIEq1D25VaJTkONyL_PDBc5dEzWC_Kwj4HJro62zEI2wyxFVqTyFxhpJ0bhe44i4UH75ufmuqa55zKbUzSJt7BUU3dqHrwphWdVuQetwm9c5rRSmSzC8qGk3H66eQw7QXHh8HH3jAdefC6UZ0UbZQ2XrLClst5GkgMCulEL_dgs1Kl9mlu4x9BnAdyRclaAeL_Xr1TjL84HnCC8jKkDjsd-nsX0tODvrvY-nfRF3AfsaGo0u1ewvpitrSvEH8t1DbcCfnptjO3n66iLS0
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEB6VVoK-cB_mXBBCvDiKr11X4qVNk4ZSRwil0BdkeQ-rUYMd5ZAQTzzwA_iN_BJm1gcNFAnxZinjJLv-xvPN7uw3AM8p7GDgJ4VLId1QiMyNtQpcFcg49H0pIkPrHcmID4_Dw5PoZANeNWdhKn2IdsGNPMO-r8nBaUH6nJfPtOl4Pv7UJdiijt42oXr3Szwq5lYtFTFMkrshr3WFqI6nvXUtGm3RxH6-iGr-WTF5nsnaUDS4Bh-bQVQVKGed1VJ21Jff9B3_d5TX4WrNUdluBaobsGGKm3A5qXfhb8G3SvJ4wcqcZQxfk6z_ibS98V__-Pp9D-OiZuOmgJ2VBaMOXyyh0r98ipBje1RPqQzLCo3Xc2qaxwYYYAkkDE179QlzRqvEeONUs91lOZsotm8qij1Z3IbjQX_cG7p1NwdXhRE-AsmjUGP6lmkeyZDnAd-JNSbFincDgYkUpybjgeRerJRvukLJOMf5RvKfezqUeXAHNouyMPeA8a7KdjQyN02ChUbHIpeYbOdaYkTOIu7Ay-appqqWOqeOG9O0SXlwVlM7qw48a01nlb7HRUYvLDRai2x-RgVxIko_jA7Snnd44L3vJenYgacNdlJ0U9p7yQpTrhapJzAvpEO9oQN3Kyy132b3_pHHOSDWUNYakAT4-ifF5NRKgRObFz4N2ILo70NI3-737cX9fzd9AleG4-QoPXo9evMAtpEq8qr67iFsLucr8wjp2FI-tl73E0ECMHE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbhNBEC2FRIq4sC_D2iCEuNjybN0TcUq8JARsRciBHJBa08soVpwZy4uEOHHgA_hGvoSqnoUYgoS4jeQa293zaupVd_UrgBcUdjDwk8KlUK1IiLSVGB22dKiSKAiUiC2tdwxH_OA4OjyJTzbgdX0WptSHaBbcyDPc-5ocfGayC04-M7btB_hLV2Ar4p2EIN17_0s7KuFOLBUhTIq7Ea9khaiMp7l1LRht0bx-voxp_lkweZHIukg0uA6f6jGUBShn7dVStfWX3-Qd_3OQN-BaxVDZbgmpm7Bh81uwPaz24G_Dt1LweMGKjKUMX5Ksf07K3vinf3z9vodR0bBxXb7OipxRfy82pMK_bIqAY3tUTaktS3OD13NqmccGGF4JIgxNu9X5ckZrxHjj1LDdZTGbaNazJcGeLO7A8aA_7h60ql4OLR3F-AQUjyODyVtqeKwinoV8JzGYEmveCQWmUZxajIeK-4nWge0IrZIMpxupf-abSGXhXdjMi9zeB8Y7Ot0xyNsMyRVak4hMYaqdGYXxOI25B6_qhyp1JXRO_Tamsk54cFalm1UPnjems1Ld4zKjlw4ZjUU6P6NyOBHLj6N92fUP9_0P3aEce_Csho5EJ6WdlzS3xWohfYFZIR3pjTy4V0Kp-Ta3848szgOxBrLGgATA1z_JJ6dOCJy4vAhowA5Dfx-CPOr13cWDfzd9CttHvYF892b09iFcRZ7Iy9K7R7C5nK_sY-RiS_XE-dxPsiovKQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+a+New+Emollient-Based+Treatment+on+Skin+Microflora+Balance+and+Barrier+Function+in+Children+with+Mild+Atopic+Dermatitis&rft.jtitle=Pediatric+dermatology&rft.au=Bianchi%2C+Pascale&rft.au=Theunis%2C+Jennifer&rft.au=Casas%2C+Christiane&rft.au=Villeneuve%2C+Cecile&rft.date=2016-03-01&rft.eissn=1525-1470&rft.volume=33&rft.issue=2&rft.spage=165&rft_id=info:doi/10.1111%2Fpde.12786&rft_id=info%3Apmid%2F27001317&rft.externalDocID=27001317
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0736-8046&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0736-8046&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0736-8046&client=summon